# Haisco Pharmaceutical Group Co., Ltd. trials: 118 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 118 trials with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor, 45 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Haisco Pharmaceutical Group Co., Ltd.: 118 rows for $5.90, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 118
- Recruiting or not yet: 45
- Read on: November 19, 2026

## Trials

The 25 newest of 118, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07920809 | A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Dermatitis Atopic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920809) |
| November 4, 2026 | NCT07915024 | Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese Participants | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Non-cystic Fibrosis Bronchiectasis (NCFBE) | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915024) |
| November 4, 2026 | NCT07915011 | Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal Impairment | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Non-cystic Fibrosis Bronchiectasis (NCFBE) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915011) |
| November 3, 2026 | NCT07913009 | Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Non-cystic Fibrosis Bronchiectasis (NCFBE) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913009) |
| August 27, 2026 | NCT07790510 | HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer | Haisco Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790510) |
| July 27, 2026 | NCT07728721 | Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728721) |
| July 13, 2026 | NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699757) |
| July 10, 2026 | NCT07695142 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid... | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor (Phase 1) | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695142) |
| June 22, 2026 | NCT07658339 | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 387 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658339) |
| June 8, 2026 | NCT07634367 | Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634367) |
| June 3, 2026 | NCT07623486 | Trial of HSK44459 Cream for the Management Plaque Psoriasis | Haisco Pharmaceutical Group Co., Ltd. | Phase 1/2 | Active not recruiting | Psoriasis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623486) |
| June 1, 2026 | NCT07616700 | A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | IgA Nephropathy (IgAN) | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616700) |
| June 1, 2026 | NCT07616375 | A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | Non-cystic Fibrosis Bronchiectasis | 669 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616375) |
| May 13, 2026 | NCT07583849 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment... | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583849) |
| May 12, 2026 | NCT07581951 | A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis) | 886 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581951) |
| May 12, 2026 | NCT07580794 | First-in-human Study of HSK56630 in Healthy Subjects | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Healthy Volunteer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07580794) |
| May 1, 2026 | NCT07561554 | Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Solid Tumors (Phase 1) | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07561554) |
| April 30, 2026 | NCT07558967 | Bioequivalence Study of Tenofovir Disoproxil Fumarate Tablets in Healthy Chinese Subjects | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Completed | Healthy | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558967) |
| April 27, 2026 | NCT07551739 | A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Pain After Surgery | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551739) |
| April 27, 2026 | NCT07551713 | Bioequivalence Study of Lidocaine and Prilocaine Cream in Healthy Chinese Subjects | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551713) |
| April 16, 2026 | NCT07533786 | A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Pain After Surgery | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533786) |
| April 9, 2026 | NCT07521345 | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healthy Subjects. | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Healhty | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07521345) |
| April 9, 2026 | NCT07519278 | Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjects | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Completed | Healthy | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519278) |
| April 9, 2026 | NCT07519070 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in... | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | IPF | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519070) |
| April 6, 2026 | NCT07510945 | HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective Surgery | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | General Anesthetic | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510945) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 48 |
| Phase 1/2 | 2 |
| Phase 2 | 38 |
| Phase 2/3 | 1 |
| Phase 3 | 25 |
| Phase 4 | 2 |
| Not applicable | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 58 |
| Recruiting | 27 |
| Not yet recruiting | 18 |
| Unknown | 9 |
| Active not recruiting | 4 |
| Enrolling by invitation | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Disease, Chronic Obstructive | 9 |
| Hemoglobinuria, Paroxysmal | 5 |
| Diabetes Mellitus, Type 2 | 5 |
| Idiopathic Pulmonary Fibrosis | 3 |
| Glomerulonephritis, IGA | 3 |
| Non-alcoholic Fatty Liver Disease | 3 |
| Renal Insufficiency | 3 |
| Agnosia | 2 |
| Pruritus | 2 |
| Psoriasis | 2 |
| Hypercholesterolemia | 1 |
| Dermatitis, Atopic | 1 |
| Glucose Intolerance | 1 |
| Prediabetic State | 1 |
| Colorectal Neoplasms | 1 |
| Recurrence | 1 |
| Pain, Postoperative | 1 |
| Paresthesia | 1 |
| Neuralgia, Postherpetic | 1 |
| Diabetic Neuropathies | 1 |
| Asthma | 1 |
| Bronchiectasis | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Colitis, Ulcerative | 1 |
| Lupus Nephritis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Clinical laboratories in the United States](https://specstream.ai/data/businesses/clinical-laboratories/united-states)
- [Commercial refrigeration companies in the United States](https://specstream.ai/data/businesses/commercial-refrigeration-companies/united-states)
- [Cosmetic dentistry practices in the United States](https://specstream.ai/data/businesses/cosmetic-dentistry-practices/united-states)
- [Cuban restaurants in the United States](https://specstream.ai/data/businesses/cuban-restaurants/united-states)
- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
